Ivan Borrello

Ivan Borrello, MD, is a scientific cofounder of WindMIL and a pioneer in the use of MILs. Dr. Borrello serves as WindMIL’s CMO while maintaining his position as an Associate Professor at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins in the divisions of Tumor Immunology and Hematologic Malignancies. He received his MD from the Medical College of Virginia. He completed his residency in Internal Medicine at the University of Chicago and his fellowship in Oncology at Johns Hopkins, where he is now the Medical Director of the Cell Therapy Laboratory as well as a faculty member. His major area of research interest has been in the development of immune-based strategies for the treatment of multiple myeloma. Specifically, his group was the first to describe the use of MILs as a source of highly tumor-specific T cells for adoptive T cell therapy.

Ivan Borrello is the Founder and Senior Clinical Advisor at WindMIL Therapeutics. With a background in Biotechnology, Ivan Borrello has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.